FIELD: pharmacology.
SUBSTANCE: invention relates to the use of cabozantinib or a pharmaceutically acceptable salt thereof for treatment of advanced renal cell carcinoma with metastases to bone or internal organs in a human patient who has previously received anti-angiogenic therapy.
EFFECT: effective agent in renal cell carcinoma treatment is proposed.
16 cl, 56 dwg, 56 tbl
Authors
Dates
2021-05-26—Published
2017-04-17—Filed